ES2356025T3 - 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor cb1. - Google Patents

1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor cb1. Download PDF

Info

Publication number
ES2356025T3
ES2356025T3 ES07871197T ES07871197T ES2356025T3 ES 2356025 T3 ES2356025 T3 ES 2356025T3 ES 07871197 T ES07871197 T ES 07871197T ES 07871197 T ES07871197 T ES 07871197T ES 2356025 T3 ES2356025 T3 ES 2356025T3
Authority
ES
Spain
Prior art keywords
phenyl
compound
yield
trifluoromethoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07871197T
Other languages
English (en)
Spanish (es)
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2356025T3 publication Critical patent/ES2356025T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES07871197T 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor cb1. Active ES2356025T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
US862540P 2006-10-23

Publications (1)

Publication Number Publication Date
ES2356025T3 true ES2356025T3 (es) 2011-04-04

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07871196T Active ES2398388T3 (es) 2006-10-23 2007-10-22 1,5-Difenil-3-piridinilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor CB1
ES07871197T Active ES2356025T3 (es) 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor cb1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES07871196T Active ES2398388T3 (es) 2006-10-23 2007-10-22 1,5-Difenil-3-piridinilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor CB1

Country Status (23)

Country Link
US (2) US7998985B2 (OSRAM)
EP (2) EP2094684B1 (OSRAM)
JP (2) JP5331001B2 (OSRAM)
KR (2) KR101088229B1 (OSRAM)
CN (2) CN101528733B (OSRAM)
AR (1) AR063497A1 (OSRAM)
AT (1) ATE492543T1 (OSRAM)
AU (1) AU2007329808B2 (OSRAM)
BR (1) BRPI0717347A2 (OSRAM)
CA (2) CA2667210C (OSRAM)
CL (1) CL2007003002A1 (OSRAM)
CY (1) CY1111140T1 (OSRAM)
DE (1) DE602007011495D1 (OSRAM)
DK (2) DK2094684T3 (OSRAM)
EA (2) EA015175B1 (OSRAM)
ES (2) ES2398388T3 (OSRAM)
MX (2) MX2009004053A (OSRAM)
PE (1) PE20080926A1 (OSRAM)
PL (2) PL2094684T3 (OSRAM)
PT (2) PT2094684E (OSRAM)
SI (2) SI2099784T1 (OSRAM)
TW (1) TW200825067A (OSRAM)
WO (2) WO2008070305A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1
WO2009131814A2 (en) * 2008-04-22 2009-10-29 Eli Lilly And Company 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
JP5539323B2 (ja) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー Cb−1リガンドとしての1,5−ジフェニル−ピロリジン−2−オン化合物
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
SG187037A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
WO2023250097A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
CA2553372A1 (en) * 2004-02-19 2005-09-01 Solvay Pharmaceuticals B.V. Imidazoline derivatives having cb1-antagonistic activity
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1

Also Published As

Publication number Publication date
TW200825067A (en) 2008-06-16
PL2094684T3 (pl) 2011-05-31
CA2667372C (en) 2013-09-03
CN101528732B (zh) 2013-04-03
US7998985B2 (en) 2011-08-16
EA200970405A1 (ru) 2009-12-30
EA015175B1 (ru) 2011-06-30
ES2398388T3 (es) 2013-03-15
PT2099784E (pt) 2013-01-04
CN101528733A (zh) 2009-09-09
KR101088236B1 (ko) 2011-11-30
AU2007329808B2 (en) 2013-11-07
KR101088229B1 (ko) 2011-11-30
CA2667372A1 (en) 2008-06-12
CA2667210A1 (en) 2008-06-12
BRPI0717347A2 (pt) 2014-01-14
WO2008070306A3 (en) 2008-07-31
WO2008070305A2 (en) 2008-06-12
PE20080926A1 (es) 2008-07-19
CL2007003002A1 (es) 2008-06-06
SI2094684T1 (sl) 2011-04-29
SI2099784T1 (sl) 2013-02-28
US8168659B2 (en) 2012-05-01
DE602007011495D1 (de) 2011-02-03
EA200970404A1 (ru) 2009-10-30
JP5331002B2 (ja) 2013-10-30
DK2094684T3 (da) 2011-03-14
PL2099784T3 (pl) 2013-05-31
JP5331001B2 (ja) 2013-10-30
CN101528732A (zh) 2009-09-09
JP2010507589A (ja) 2010-03-11
DK2099784T3 (da) 2013-01-14
AR063497A1 (es) 2009-01-28
EP2099784A2 (en) 2009-09-16
AU2007329807A1 (en) 2008-06-12
CY1111140T1 (el) 2015-06-11
EP2094684B1 (en) 2010-12-22
US20090275618A1 (en) 2009-11-05
CN101528733B (zh) 2013-10-16
US20100016375A1 (en) 2010-01-21
KR20090071613A (ko) 2009-07-01
PT2094684E (pt) 2011-01-28
EA015745B1 (ru) 2011-10-31
WO2008070306A2 (en) 2008-06-12
AU2007329808A1 (en) 2008-06-12
EP2099784B1 (en) 2012-12-12
MX2009004054A (es) 2009-04-27
JP2010507590A (ja) 2010-03-11
MX2009004053A (es) 2009-04-27
KR20090069316A (ko) 2009-06-30
CA2667210C (en) 2013-09-24
EP2094684A2 (en) 2009-09-02
ATE492543T1 (de) 2011-01-15
WO2008070305A3 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ES2356025T3 (es) 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-onas como moduladores del receptor cb1.
KR100868353B1 (ko) 도파민 d4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
ES2334998T3 (es) Derivado de 2-oxo-1-pirrolidina y sus usos farmaceuticos.
US10717725B2 (en) Pyrrolidine GPR40 modulators
ES2467701T3 (es) Derivados de isoxazol-piridazina
RS56163B1 (sr) Supstituisani pirolidin-2-karboksamidi
ES2323313T3 (es) Derivados de imidazol, procedimientos para prepararlos y sus usos.
US20100035862A1 (en) Novel aza-cyclic indole-2-carboxamides and methods of use thereof
KR20150082616A (ko) 디히드로피라졸 gpr40 조절제
KR20100082349A (ko) 치환된 n-페닐-비피롤리딘 우레아 및 이의 치료적 용도
US20080081833A1 (en) Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
JP2006525302A (ja) ニコチン性アセチルコリン受容体の正のモジュレーター
US20080051441A1 (en) Aryl Sulphonamide Modulators
JP2020500908A (ja) Ccr2/ccr5受容体拮抗剤としてのビフェニル化合物
CN102112469B (zh) 神经元nAChR的安静减敏剂及其使用方法
ES2335305T3 (es) Derivados de pirrolidina como antagonistas del receptor h3 de histamina.
JP6490187B2 (ja) 置換アザスピロ(4.5)デカン誘導体
AU2007329807B2 (en) 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulator
Katzman Navigating the Roads to Drug Discovery Part 1: Design, Synthesis, and Biological Evaluation of a Novel Class of Allosteric Modulators of N-Methyl-D-Aspartate Receptor Function Part 2: Discovery of Novel Tetrahydroisoquinoline (THIQ)-Based CXCR4 Antagonists and Conformational Analysis of Structurally Similar CXCR4 Antagonists